Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including one child. 

One of the trials had focused on assessing a potential treatment for acute myeloid leukemia (AML), a type of blood cancer, while the other trial had aimed to test a new agent targeting ovarian cancer.

“The field of pediatric oncology is small, and we go into it to figure out ways to cure patients of their childhood cancers, and that’s what we’re all dedicated to doing. So anytime something like this happens, it’s devastating for the family and the team,” Gardner said.

Gardner added that the death was a recent event. Three other patients have been given a lower dosage of the therapy, according to CNN.  

Also Read: Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

The second study, which focused on ovarian cancer, was in phase three — or the final stage just before a company seeks FDA approval for a drug.

According to CNN, Mersana said on Thursday that the FDA had implemented a partial clinical hold due to fatal bleeding events involving five study participants. The company said that approximately 560 individuals have received the study drug thus far.

Now Read: FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder

Photo: Shutterstock